Meryl Stav
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Meryl Stav has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Amber Dahlin
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
3 shared publications- Jessica Lasky-Su
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
3 shared publications Mengna Huang
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
3 shared publicationsPei Zhang
Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
3 shared publications- Priyadarshini Kachroo
Department of Health Informatics, Rutgers School of Health Professions, Rutgers-The State University of New Jersey, Newark, United States
3 shared publications - Rachel Sabine Kelly
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA, USA.
3 shared publications
Latest Publications
- Open Access
- 19 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 545
The ratio of circulatory levels of sphingolipids to steroids predicts asthma exacerbations
The lack of biomarkers to identify individuals at risk of asthma exacerbations remains a significant limitation to improving patient outcomes. To address this need, we analyze data from three asthma cohorts, combining up to 25 years of electronic medical records with sequential metabolomics studies, to develop and replicate a predictive model for asthma exacerbation risk. We identify asthma-associated biochemical pathways via global circulatory metabolomics and then apply targeted mass spectrometry methods to quantify selected steroids, sphingolipids, and microbial-derived metabolites. The sphingolipid-to-steroid ratios robustly associate with 5-year exacerbation risk (discovery p value = 1.63×10⁻26-0.029; replication p value = 1.89×10⁻36-0.033). Based upon these findings, we derive and replicate a simple 5-year predictive model of asthma exacerbations using 21 sphingolipid-to-steroid ratios that outperforms current clinical measures (discovery AUC = 0.90; replication AUC = 0.89). These findings underscore the value of metabolomic profiling to develop a practical, cost-effective clinical assay for asthma exacerbation risk that may improve patient care.
- 19 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 545
Open AccessThe ratio of circulatory levels of sphingolipids to steroids predicts asthma exacerbations
The lack of biomarkers to identify individuals at risk of asthma exacerbations remains a significant limitation to improving patient outcomes. To address this need, we analyze data from three asthma cohorts, combining up to 25 years of electronic medical records with sequential metabolomics studies, to develop and replicate a predictive model for asthma exacerbation risk. We identify asthma-associated biochemical pathways via global circulatory metabolomics and then apply targeted mass spectrometry methods to quantify selected steroids, sphingolipids, and microbial-derived metabolites. The sphingolipid-to-steroid ratios robustly associate with 5-year exacerbation risk (discovery p value = 1.63×10⁻26-0.029; replication p value = 1.89×10⁻36-0.033). Based upon these findings, we derive and replicate a simple 5-year predictive model of asthma exacerbations using 21 sphingolipid-to-steroid ratios that outperforms current clinical measures (discovery AUC = 0.90; replication AUC = 0.89). These findings underscore the value of metabolomic profiling to develop a practical, cost-effective clinical assay for asthma exacerbation risk that may improve patient care.
- 20 July 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (8) , 1723
Author Correction: Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma
- 20 July 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (8) , 1723
Author Correction: Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma
- Top Cited Papers
- 21 March 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (4) , 814-822
Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma
The application of large-scale metabolomic profiling provides new opportunities for realizing the potential of omics-based precision medicine for asthma. By leveraging data from over 14,000 individuals in four distinct cohorts, this study identifies and independently replicates 17 steroid metabolites whose levels were significantly reduced in individuals with prevalent asthma. Although steroid levels were reduced among all asthma cases regardless of medication use, the largest reductions were associated with inhaled corticosteroid (ICS) treatment, as confirmed in a 4-year low-dose ICS clinical trial. Effects of ICS treatment on steroid levels were dose dependent; however, significant reductions also occurred with low-dose ICS treatment. Using information from electronic medical records, we found that cortisol levels were substantially reduced throughout the entire 24-hour daily period in patients with asthma who were treated with ICS compared to those who were untreated and to patients without asthma. Moreover, patients with asthma who were treated with ICS showed significant increases in fatigue and anemia as compared to those without ICS treatment. Adrenal suppression in patients with asthma treated with ICS might, therefore, represent a larger public health problem than previously recognized. Regular cortisol monitoring of patients with asthma treated with ICS is needed to provide the optimal balance between minimizing adverse effects of adrenal suppression while capitalizing on the established benefits of ICS treatment.
- 21 March 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (4) , 814-822
Top Cited PapersMetabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma
The application of large-scale metabolomic profiling provides new opportunities for realizing the potential of omics-based precision medicine for asthma. By leveraging data from over 14,000 individuals in four distinct cohorts, this study identifies and independently replicates 17 steroid metabolites whose levels were significantly reduced in individuals with prevalent asthma. Although steroid levels were reduced among all asthma cases regardless of medication use, the largest reductions were associated with inhaled corticosteroid (ICS) treatment, as confirmed in a 4-year low-dose ICS clinical trial. Effects of ICS treatment on steroid levels were dose dependent; however, significant reductions also occurred with low-dose ICS treatment. Using information from electronic medical records, we found that cortisol levels were substantially reduced throughout the entire 24-hour daily period in patients with asthma who were treated with ICS compared to those who were untreated and to patients without asthma. Moreover, patients with asthma who were treated with ICS showed significant increases in fatigue and anemia as compared to those without ICS treatment. Adrenal suppression in patients with asthma treated with ICS might, therefore, represent a larger public health problem than previously recognized. Regular cortisol monitoring of patients with asthma treated with ICS is needed to provide the optimal balance between minimizing adverse effects of adrenal suppression while capitalizing on the established benefits of ICS treatment.